Onconova Therapeutics (NASDAQ: ONTX) Reduced to Hold at Zacks Investment Research

NASDAQ: ONTX was reduced by Zacks  from a “buy” score to a “hold” rating in a research note released to financiers on Thursday, Zacks.com records.

According to Zacks, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on uncovering and developing little molecule medication candidates to treat cancer. The Firm‘s items under different phases of development consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 as well as Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

A number of various other equities research experts likewise recently talked about the company. Noble Financial reissued a “acquire” score and also released a $11.00 cost goal on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their price target on Onconova Therapeutics from $29.00 to $12.00 as well as set a “get” score on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and a twelve month high of $28.95. Business has a 50 day relocating average price of $2.90 and a two-hundred day moving average price of $4.16. The company has a market cap of $46.76 million, a P/E proportion of -1.82 as well as a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last launched its quarterly incomes outcomes on Thursday, November 11th. The biopharmaceutical business reported ($ 0.22) earnings per share for the quarter, topping experts’ consensus quotes of ($ 0.33) by $0.11. Onconova Therapeutics had an adverse return on equity of 59.78% and also an unfavorable internet margin of 8,294.27%. The company had earnings of $0.06 million during the quarter, contrasted to the agreement estimate of $0.06 million. Throughout the same quarter in the previous year, the company uploaded ($ 0.45) EPS. As a group, research analysts forecast that Onconova Therapeutics will certainly publish -1.18 EPS for the existing year.

A variety of hedge funds have actually recently bought and sold shares of ONTX. GSA Resources Partners LLP purchased a new setting in Onconova Therapeutics throughout the 3rd quarter worth $922,000. Hudson Bay Capital Administration LP purchased a brand-new setting in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC bought a new position in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC purchased a new placement in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Lastly, Dimensional Fund Advisors LP bought a new placement in shares of Onconova Therapeutics in the 2nd quarter worth $509,000. Hedge funds and various other institutional investors have 13.36% of the firm’s stock.

About Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical firm, which participates in the recognition as well as development of oncology therapeutics. It concentrates on uncovering and also creating tiny particle medication prospects to deal with cancer cells. The firm was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 as well as is headquartered in Newtown, PA

. Get a free duplicate of the Zacks research report on Onconova Therapeutics (ONTX).

For additional information concerning research offerings from Zacks Investment Research, go to Zacks.com.

This instant news alert was created by narrative scientific research modern technology as well as financial information from Market in order to provide visitors with the fastest and most accurate coverage. This story was reviewed by Market’s content team prior to magazine. 



Prior to you think about Onconova Therapeutics, you’ll want to hear this.

Market keeps track of Wall Street’s top-rated as well as best performing research experts as well as the stocks they suggest to their clients each day. Market has actually identified the five stocks that top analysts are quietly whispering to their clients to acquire now prior to the wider market catches on … and Onconova Therapeutics wasn’t on the list.

While Onconova Therapeutics currently has a “Buy” score among experts, premier analysts believe these five stocks are much better acquires.

Main Menu